Why it’s time to rethink your DNA: Four considerations for going cell-free
For decades, plasmid DNA (pDNA) has been widely used as a tool to enable the development of many advanced therapeutics. However, as these downstream applications have become more complex and timelines more demanding, the limitations of plasmid DNA manufacturing have become increasingly apparent. Challenges such as sequence instability, toxicity to host cells and lengthy production timelines can introduce delays, variability, and design compromises.
In response to this landscape change, alternative approaches such as cell-free DNA are gaining traction. For organisations evaluating whether to adopt synthetic, cell-free DNA, the decision extends beyond technical preference. It reflects a broader shift in how research and development workflows are structured and optimised.
1. Sequence flexibility: Supporting complex sequence design
Traditional pDNA production methods are inherently influenced by biological constraints, due the bacterial fermentation step. Sequences that are unstable, repetitive, or toxic to host cells often require modification, optimisation, or may be excluded entirely.
Cell-free DNA removes these constraints as the manufacturing process is entirely enzymatic. Complex sequences, including those with high G-C content, long polyA tails, or ITRs/LTRs are maintained throughout the amplification process. This enables the transition to flexible sequence design, without the restrictions enforced by bacterial fermentation processes.
2. Workflow efficiency through application specific DNA designs
Opting for synthetic DNA can streamline your workflows and increase efficiency. 4basebio’s opDNA® template, designed for mRNA manufacturing, features a 3’ open end that feeds directly into IVT reactions, removing the need for linearisation and simplifying the production process.
Similarly, 4basebio’s hpDNA constructs, ideal for AAV manufacturing, enable a reduction in the mass of DNA required to achieve equivalent titres compared to pDNA. This increases process efficiency while also reducing material usage and associated costs. Together, these advances support a shift towards more streamlined, efficient workflows, particularly in applications where scalability and reproducibility are critical.
3. Speed and scalability at GMP: Reaching the clinic faster
Traditional pDNA manufacturing involves complex processes from master cell banking and bacterial fermentation to multiple downstream purification steps. These requirements can slow down manufacturing timelines, introduce variability, lead to batch failures, and often require extensive optimisation. With synthetic DNA, these constraints are significantly reduced.
By removing the need for bacterial fermentation, synthetic DNA enables faster turnaround times, improved consistency, and a more predictable manufacturing process at GMP. Importantly, this approach is inherently scalable, providing a clear pathway from late-stage discovery through to clinical and commercial manufacturing without the need to fundamentally redesign processes. As the industry continues to prioritise speed, reliability, and scalability, synthetic DNA is increasingly positioned as a key enabler of clinical and therapeutic innovation.
4. Improving the safety profile of DNA starting materials
Plasmid DNA manufacturing introduces several inherent safety considerations due to its reliance on bacterial systems. These include the presence of backbone sequences such as antibiotic resistance markers, as well as potential contamination with endotoxins, host cell impurities, and bioburden.
Synthetic DNA manufacturing utilizes an enzymatic amplification process, eliminating the need for bacterial fermentation. The absence of bacterial backbone sequences and reduced exposure to host-derived contaminants supports a cleaner manufacturing process.
What this means for you?
For scientists and organisations developing nucleic acid-based therapeutics, the choice of starting material has direct implications for both development strategy and clinical readiness. Synthetic, cell-free DNA offers a more controlled and defined manufacturing approach compared to pDNA, helping to reduce upstream risks at the source. By removing the need for bacterial production systems, it supports a cleaner starting material with improved consistency and a more predictable quality profile. This can translate into greater confidence in downstream development, from early research through to clinical manufacturing.
Want to make the switch? Explore strategic and regulatory considerations
Taking the next step with cell-free DNA
As the demands placed on DNA continue to evolve, so must the technologies used to produce it. What was once sufficient for basic research may no longer meet the needs of complex, fast-paced, and clinically driven applications.
By enabling greater sequence flexibility, streamlining processes, and supporting both speed and scalability, synthetic DNA solutions offer a compelling alternative to traditional approaches.
For organisations seeking to accelerate development and reduce risk, the shift towards synthetic DNA represents a strategic advantage in developing next generation therapies.
